Medical Scientific Bulletin of Central Chernozemye (Naučno-medicinskij vestnik Centralʹnogo Černozemʹâ)Medical Scientific Bulletin of Central Chernozemye (Naučno-medicinskij vestnik Centralʹnogo Černozemʹâ)1990-472XФедеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации800310.18499/1990-472X-2022-0-90-67-75Original ArticleCURRENT VIEWS ON THE TREATMENT OF HORMONALLY ACTIVE NEUROENDOCRINE TUMORS OF THE PANCREAS, EXCLUDING INSULINOMAChernykhT. M-MalyuginD. A-KhachaturovM. V-ZoloedovV. I-Voronezh State Medical UniversityFirst Moscow State Medical University named after I.M. Sechenov1512202290677522012023Copyright © 2022, Medical Scientific Bulletin of Central Chernozemye (Naučno-medicinskij vestnik Centralʹnogo Černozemʹâ)2022The prevalence of neuroendocrine tumors (NETs) has been increasing in recent years. The most common localization of NET is the gastric-intestinal tract, in particular the pancreas (PV). Among hormonally active NETs, the most common are insulinoma, gastrinoma, glucagonoma and VIPoma. The treatment of the latter three is rarely addressed in the scientific literature due to their low prevalence. The purpose of this review is to summarize the latest information on the treatment of hormone-active RV tumors such as gastrinoma, VIPom and glucagonoma (excluding insulin). For treatment with gastrin, symptomatic therapy is used, including antisecretory drugs (mainly proton pump inhibitors), surgical treatment is currently used more often than in the past. Symptomatic therapy also plays a major role in the treatment of VIP, since the tumor is often malignant, and by the time of diagnosis, most patients have metastases. Symptomatic treatment includes replenishment of fluid and electrolytes, including with the help of infusion therapy, administration of somatostatin analogues, antidiarrheal agents. Somatostatin analogues, resection of the primary pancreatic tumor are used for glucagon treatment. In metastatic-advanced NETs, surgical treatment, tumor embolization, ablation, targeted therapy, and in some cases liver transplantation are used.neuroendocrine tumorpancreasgastrinomaglucagonomaVIPomatreatmentнейроэндокринная опухольподжелудочная железагастриномаглюкагономаВИПомалечение[Ассоциация онкологов России, Российское общество клинической онкологии, Российская Ассоциация Эндокринологов. Федеральные клинические рекомендации по нейроэндокринным опухолям. Доступ по ссылке: https://oncology-association.ru/clinicalguidelines][Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121(4):589-597. doi:10.1002/cncr.29099][G. Muscogiuri, B. Altieri, M. Albertelli, A. Dotto, R. Modica, L. Barrea, G. Fanciulli, T. Feola, R. Baldelli, R.M.Ruggeri, M. Gallo, V. Guarnotta, P. Malandrino, E. Messina, M.A. Venneri, E. Giannetta, D. Ferone, A. Colao, A. Faggiano. Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective. Endocrine. 2020 Aug;69(2):441-450. doi: 10.1007/s12020- 020-02331-3][M. H. Kulke, ‘Somatostatin Analogues in Neuroendocrine Tumors’, J Natl Compr Canc Netw, vol. 14, no. 3, pp. 241-242, Mar. 2016, doi: 10.6004/jnccn.2016.0029.][Орел Н.Ф., Артамонова Е.В., Горбунова В.А., Делекторская В.В., Емельянова Г.С., Любимова Н.В. и соавт. Практические рекомендации по лекарственному лечению нейроэндокринных неоплазий желудочно-кишечного тракта, поджелудочной железы и других локализаций. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2021 (том 11). 30][R.T. Jensen, T. Ito. Gastrinoma. In: Feingold KR, Anawalt B, Boyce A, et al., eds. Endotext. South Dartmouth (MA): MDText.com, Inc.; November 21, 2020.][Lundell L, Vieth M, Gibson F, Nagy P, Kahrilas PJ. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther. 2015;42(6):649-663. doi:10.1111/apt.13324][T. Ito, H. Igarashi, H. Uehara, and R. T. Jensen, ‘Pharmacotherapy of Zollinger-Ellison syndrome’, Expert Opinion on Pharmacotherapy, vol. 14, no. 3, pp. 307-321, Feb. 2013, doi: 10.1517/14656566.2013.767332.][M. Falconi et al., ‘ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors’, Neuroendocrinology, vol. 103, no. 2, pp. 153-171, 2016, doi: 10.1159/000443171.][R. T. Jensen et al., ‘ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms: Functional Pancreatic Endocrine Tumor Syndromes’, Neuroendocrinology, vol. 95, no. 2, pp. 98-119, 2012, doi: 10.1159/000335591.][C. L. Lopez et al., ‘Minimally Invasive Versus Open Pancreatic Surgery in Patients with Multiple Endocrine Neoplasia Type 1’, World J Surg, vol. 40, no. 7, pp. 1729-1736, Jul. 2016, doi: 10.1007/s00268-016-3456-7.][T. Ito and R. T. Jensen, ‘Imaging in multiple endocrine neoplasia type 1: recent studies show enhanced sensitivities but increased controversies’, International Journal of Endocrine Oncology, vol. 3, no. 1, pp. 53-66, Feb. 2016, doi: 10.2217/ije.15.29.][T. Ito, H. Igarashi, and R. T. Jensen, ‘Pancreatic neuroendocrine tumors: Clinical features, diagnosis and medical treatment: Advances’, Best Practice & Research Clinical Gastroenterology, vol. 26, no. 6, pp. 737-753, Dec. 2012, doi: 10.1016/j.bpg.2012.12.003.][G. K. Dimitriadis, M. O. Weickert, H. S. Randeva, G. Kaltsas, and A. Grossman, ‘Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours’, Endocrine-Related Cancer, vol. 23, no. 9, pp. R423-R436, Sep. 2016, doi: 10.1530/ERC-16-0200.][Adam N, Lim SS, Ananda V, Chan SP. VIPoma syndrome: challenges in management. Singapore Med J. 2010;51(7):e129-e132.][O.A. Belei, E.R. Heredea, E. Boeriu, et al. Verner-Morrison syndrome. Literature review. Rom J Morphol Embryol. 2017;58(2):371-376.][V. E. Zagainov, V. A. Belskii, K. G. Korneva, D. M. Kuchin, and A. A. Baranova, ‘A rare case report of surgical treatment of pancreatic VIPoma’, Ann. hir. gepatol., vol. 25, no. 1, pp. 113- 118, Mar. 2020, doi: 10.16931/1995-5464.20201113-118.][Schizas D, Mastoraki A, Bagias G, et al. Clinicopathological data and treatment modalities for pancreatic vipomas: a systematic review. J BUON. 2019;24(2):415-423.][Partelli S, Bartsch DK, Capdevila J, et al. ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours. Neuroendocrinology. 2017;105(3):255-265. doi:10.1159/000464292][Ueda Y, Toyama H, Terai S, et al. Gan To Kagaku Ryoho. 2017;44(12):1976-1978.][J. K. Ramage et al., ‘Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)’, Gut, vol. 61, no. 1, pp. 6-32, Jan. 2012, doi: 10.1136/gutjnl-2011-300831.][A. A. Oak, P. D. Chhetri, A. Rivera, A. S. Verkman, and O. Cil, ‘Repurposing calcium sensing receptor agonist cinacalcet for treatment of CFTR-mediated secretory diarrheas’, JCI Insight, Jan. 2021, doi: 10.1172/jci.insight.146823.][Norton JA, Harris EJ, Chen Y, et al. Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection. Arch Surg. 2011;146(6):724-732. doi:10.1001/archsurg.2011.129][Frilling A, Modlin IM, Kidd M, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15(1):e8-e21. doi:10.1016/S1470-2045(13)70362-0][Kimbara S, Fujiwara Y, Toyoda M, et al. Rapid improvement of glucagonoma-related necrolytic migratory erythema with octreotide. Clin J Gastroenterol. 2014;7(3):255-259. doi:10.1007/s12328-014-0471-9][Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors [published correction appears in N Engl J Med. 2011 Mar 17;364(11):1082]. N Engl J Med. 2011;364(6):501-513. doi:10.1056/NEJMoa1003825][Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514-523. doi:10.1056/NEJMoa1009290][C. G. Tran, S. K. Sherman, C. Chandrasekharan, and J. R. Howe, ‘Surgical Management of Neuroendocrine Tumor Liver Metastases’, Surgical Oncology Clinics of North America, vol. 30, no. 1, pp. 39-55, Jan. 2021, doi: 10.1016/j.soc.2020.08.001.][W. T. Zandee et al., ‘Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors’, The Journal of Clinical Endocrinology & Metabolism, vol. 104, no. 4, pp. 1336-1344, Apr. 2019, doi: 10.1210/jc.2018- 01991.][W. Makis, K. McCann, T. A. Riauka, and A. J. B. McEwan, ‘Glucagonoma Pancreatic Neuroendocrine Tumor Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy’, Clinical Nuclear Medicine, vol. 40, no. 11, pp. 877-879, Nov. 2015, doi: 10.1097/RLU.0000000000000891.]